SUPPORTING HEALTH INNOVATIONS
WHEREVER IT IS CHALLENGING
UPCOMING EVENTS
29. 5.
2024
15:30
Czech Institute of Informatics, Robotics and Cybernetics (CIIRK), Jugoslávských partizánů 1580/3, Prague 6, 160 00, A-303 Blue classroom
Light to health: HTA methodologies for medical devices: Costs and budget impact analysis
Lecture: HTA methodologies for medical devices: Costs and budget impact analysis
PRACTICAL WORKSHOP
A cost structure for use in BIA and other cost analyzes in the evaluation of medical devices
BIA – structure, basic characteristics for creating individual scenarios, budget impact model, interpretation of results
Please remember to bring your computer!
Click here for online registration
CEEOR PUBLICATIONS
Bušányová B, Vajter M, Kelifová S, Lišková P, Miková H, Breciková K, Žigmond J, Rogalewicz V, Tichopád A, Višňanský M, Šarkanová I.
Leber hereditary optic neuropathy in Czechia and Slovakia: Quality of life and costs from patient perspective.
Heliyon. 2024. VOLUME 10, ISSUE 11, E32296.
Tichopád A, Žigmond J, Jeseňák M, Solovič I, Breciková K, Rybář M, Rožánek M, Sedlák V.
Adherence to application technique of inhaled corticosteroid in patients with asthma and COVID-19 improves outcomes.
BMJ Open Respiratory Research 2024;11:e001874.
Hospodková P, Karásek P, Tichopád A.
Stakeholder Insights into Czech Performance-Based Managed Entry Agreements: Potential for Transformative Change in Pharmaceutical Access?
Healthcare. 2024; 12(1):119.
Hospodková P, Gilíková K, Barták M, Marušáková E, Tichopád A.
Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective.
Healthcare. 2023; 11(8):1179.
Tichopád A,
Partially Autonomous Information System Facilitating Performance-based Managed Entry Agreements in Slovakia.
2022 E-Health and Bioengineering Conference (EHB), Iasi, Romania, 2022, pp. 1-4, doi: 10.1109/EHB55594.2022.9991597.
Vrablík M, Šarkanová I, Breciková K, Šedová P, Šatný M, Tichopád A,
Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias.
PLoS ONE, 2023, 18(5): e0272883.
Müllerová J., Žigmond J.,
Mapovanie liečby dospelých pacientov s relapsujúcou alebo refraktérnou B-bunkovou akútnou lymfoblastovou leukémiou (B-ALL) na Slovensku.
Bratislava, CEEOR 2023. Vydané ako elektronická publikácia č. 2023/04, CEEOR, 2023, 15 s. ISBN 978-80-974515-3-0.
Šarkanová I., Szépe, V.,
Novorodenci so syndrómom krátkeho čreva v Slovenskej republike 2017 – 2021.
Bratislava, CEEOR 2023. Vydané ako elektronická publikácia č. 2023/03, CEEOR, 2023, 17 s. ISBN 978-80-974515-1-6.
Šarkanová I., Szarvašová, Z.,
Komplexné perianálne fistuly pri Crohnovej chorobe: Deskriptívna analýza veľkosti populácie v Slovenskej republike.
Bratislava, CEEOR 2023. Vydané ako elektronická publikácia č. 2023/01, CEEOR, 2019, 18 s. ISBN 978-80-974515-0-9.
PATIENTS, HEALTH CARE PRACTITIONERS, OUR CLIENTS AND THE WHOLE SOCIETY BENEFIT FROM CEEOR‘S DATA, CONSULTING AND COMMISSIONED RESEARCH.
PFIZER
Our experience with CEEOR was excellent. Because of their insight and establishment in the Europe region, we were able to set up and conduct our non-interventional study successfully. Their staff is experienced and dedicated, this made our communication seamless, and our project completed as planned.
Moh-Lim Ong
Sr. Director Global Medical Affairs, Rare Disease, Global Innovative Products, Pfizer Inc.
GSK
CEEOR is a very professional and reliable partner. During our cooperation for HO studies, I truly appreciated the high expertise and quality of the work provided by CEEOR. The team has a very good understanding of the local healthcare environment, including systems & procedures in the respective countries meaning an important asset when performing projects.
Brigitte Sloesen
HE&PH for Vaccines Europe at GSK
